We classify licensing contracts into four stages: (i) drug discovery, (ii) early development, (iii) late development, and (iv) marketing. Estimates from random effect IV models reveal that fewer drug candidates in either late development or marketing stages accelerate license-ins in various stages.

On the other hand, richer pipelines in any stage facilitate license-outs in that stage. In addition, theoretical implications are discussed.